investment In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and biotech companies over the last fifteen years, and goes in-depth into the company’s innovative pipeline, including UBI’s possible HIV cure.…
CEO story In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her own personal history that led her to the creation of the company. To read the first part of this interview,…
Inlicensing The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development ecosystem in Taiwan, and the acquire-develop-transfer model of doing business. Throughout our interviews in Taiwan, several industry stakeholders have expressed…
investment Cormac Callaghan, founder and managing director of Primecore, a portfolio and program management consultancy based in Dublin and Cambridge, Massachusetts, has managed large-scale change programs for the pharmaceutical industry for the better part of 30 years. He has seen his share of setbacks: between 2006 and 2008, Callaghan was the…
BCF Business Law Gino Martel explains the present environment for M&As, divestitures and out-licensing in the Canadian biotech sector, the different ways that biotech companies can commercialize their scientific successes in the current market climate, and strategies for keep scientific talent in Canada. How do mergers and acquisitions in the pharmaceutical industry in…
Biotech City The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government funded cluster of 80 companies and over 5,000 employees. Your background has a strong focus on business start-ups and development,…
Bavarian Nordic If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…
Biotechnology The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic shift towards becoming a semi-virtual model company. He also considers the importance of creating global links to capital as a…
Government Regulation President Santos appointed economist Alejandro Gaviria as the new Minister of Health and Social Protection in September 2012. Gaviria’s priority has been to create health reform that would introduce the next episode of Colombia’s payer system, following the introduction of Law 100 in 1993, which extended health coverage to…
Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…
drug development BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector on a national level, and offers perspectives on tax policy and its impact on drug development. How does BIOTECanada actively…
JHL Biotech Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might indeed liken ourselves to a kitchen. But I would add this: there are a lot of cookbooks out there, but…
See our Cookie Privacy Policy Here
